The expanding therapeutic armamentarium for inflammatory bowel disease: How to choose the right drug[s] for our patients?

Pieter Hindryckx; Pieter Hindryckx; Niels Vande Casteele; Niels Vande Casteele; Gregor Novak; Gregor Novak; Reena Khanna; Reena Khanna; Geert D'Haens; Geert D'Haens; William J. Sandborn; William J. Sandborn; Silvio Danese; Vipul Jairath; Vipul Jairath; Vipul Jairath; Brian G. Feagana; Brian G. Feagana

doi:10.1093/ecco-jcc/jjx117

The expanding therapeutic armamentarium for inflammatory bowel disease: How to choose the right drug[s] for our patients?

Pieter Hindryckx, Pieter Hindryckx, Niels Vande Casteele, Niels Vande Casteele, Gregor Novak, Gregor Novak, Reena Khanna, Reena Khanna, Geert D'Haens, Geert D'Haens, William J. Sandborn, William J. Sandborn, Silvio Danese, Vipul Jairath, Vipul Jairath, Vipul Jairath, Brian G. Feagana, Brian G. Feagana

Istituto Clinico Humanitas

Research output: Contribution to journal › Review article › peer-review

Abstract

© 2017 European Crohn's and Colitis Organisation (ECCO). Published by Oxford University Press. All rights reserved. The therapeutic landscape for inflammatory bowel disease [IBD] is rapidly evolving. Two new biologic drugs, vedolizumab and ustekinumab, have recently entered the marketplace, the first biosimilars have been introduced, and several other agents are at an advanced stage of clinical development. In parallel, therapeutic goals have shifted from symptom control towards mucosal healing and prevention of bowel damage. In the coming years, gastroenterologists will be faced with unprecedented choices when selecting the best treatment for their patients with IBD. In this article, we review existing data on the mechanisms of action, efficacy, and safety of recently approved and late-stage pipeline therapies, and use this information to speculate on the positioning of these drugs, alone or in combination, in therapeutic algorithms for Crohn's disease and ulcerative colitis.

Original language	English
Pages (from-to)	105-109
Number of pages	5
Journal	Journal of Crohn's and Colitis
Volume	12
Issue number	1
DOIs	https://doi.org/10.1093/ecco-jcc/jjx117
Publication status	Published - Jan 1 2018

Keywords

IL-23 antagonists
Inflammatory bowel disease
JAK inhibitors
Pipeline
Smad7
Sphingosine-1 phosphate
Therapy
TNF antagonists

Access to Document

10.1093/ecco-jcc/jjx117

Cite this

Hindryckx, P., Hindryckx, P., Casteele, N. V., Casteele, N. V., Novak, G., Novak, G., Khanna, R., Khanna, R., D'Haens, G., D'Haens, G., Sandborn, W. J., Sandborn, W. J., Danese, S., Jairath, V., Jairath, V., Jairath, V., Feagana, B. G., & Feagana, B. G. (2018). The expanding therapeutic armamentarium for inflammatory bowel disease: How to choose the right drug[s] for our patients? Journal of Crohn's and Colitis, 12(1), 105-109. https://doi.org/10.1093/ecco-jcc/jjx117

The expanding therapeutic armamentarium for inflammatory bowel disease: How to choose the right drug[s] for our patients? / Hindryckx, Pieter; Hindryckx, Pieter; Casteele, Niels Vande; Casteele, Niels Vande; Novak, Gregor; Novak, Gregor; Khanna, Reena; Khanna, Reena; D'Haens, Geert; D'Haens, Geert; Sandborn, William J.; Sandborn, William J.; Danese, Silvio; Jairath, Vipul; Jairath, Vipul; Jairath, Vipul; Feagana, Brian G.; Feagana, Brian G.

In: Journal of Crohn's and Colitis, Vol. 12, No. 1, 01.01.2018, p. 105-109.

Research output: Contribution to journal › Review article › peer-review

Hindryckx, P, Hindryckx, P, Casteele, NV, Casteele, NV, Novak, G, Novak, G, Khanna, R, Khanna, R, D'Haens, G, D'Haens, G, Sandborn, WJ, Sandborn, WJ, Danese, S, Jairath, V, Jairath, V, Jairath, V, Feagana, BG & Feagana, BG 2018, 'The expanding therapeutic armamentarium for inflammatory bowel disease: How to choose the right drug[s] for our patients?', Journal of Crohn's and Colitis, vol. 12, no. 1, pp. 105-109. https://doi.org/10.1093/ecco-jcc/jjx117

Hindryckx, Pieter ; Hindryckx, Pieter ; Casteele, Niels Vande ; Casteele, Niels Vande ; Novak, Gregor ; Novak, Gregor ; Khanna, Reena ; Khanna, Reena ; D'Haens, Geert ; D'Haens, Geert ; Sandborn, William J. ; Sandborn, William J. ; Danese, Silvio ; Jairath, Vipul ; Jairath, Vipul ; Jairath, Vipul ; Feagana, Brian G. ; Feagana, Brian G. / The expanding therapeutic armamentarium for inflammatory bowel disease: How to choose the right drug[s] for our patients?. In: Journal of Crohn's and Colitis. 2018 ; Vol. 12, No. 1. pp. 105-109.

@article{493fc94f79e841d79943c12c5c95e734,

title = "The expanding therapeutic armamentarium for inflammatory bowel disease: How to choose the right drug[s] for our patients?",

abstract = "{\textcopyright} 2017 European Crohn's and Colitis Organisation (ECCO). Published by Oxford University Press. All rights reserved. The therapeutic landscape for inflammatory bowel disease [IBD] is rapidly evolving. Two new biologic drugs, vedolizumab and ustekinumab, have recently entered the marketplace, the first biosimilars have been introduced, and several other agents are at an advanced stage of clinical development. In parallel, therapeutic goals have shifted from symptom control towards mucosal healing and prevention of bowel damage. In the coming years, gastroenterologists will be faced with unprecedented choices when selecting the best treatment for their patients with IBD. In this article, we review existing data on the mechanisms of action, efficacy, and safety of recently approved and late-stage pipeline therapies, and use this information to speculate on the positioning of these drugs, alone or in combination, in therapeutic algorithms for Crohn's disease and ulcerative colitis.",

keywords = "IL-23 antagonists, Inflammatory bowel disease, JAK inhibitors, Pipeline, Smad7, Sphingosine-1 phosphate, Therapy, TNF antagonists",

author = "Pieter Hindryckx and Pieter Hindryckx and Casteele, {Niels Vande} and Casteele, {Niels Vande} and Gregor Novak and Gregor Novak and Reena Khanna and Reena Khanna and Geert D'Haens and Geert D'Haens and Sandborn, {William J.} and Sandborn, {William J.} and Silvio Danese and Vipul Jairath and Vipul Jairath and Vipul Jairath and Feagana, {Brian G.} and Feagana, {Brian G.}",

year = "2018",

month = jan,

day = "1",

doi = "10.1093/ecco-jcc/jjx117",

language = "English",

volume = "12",

pages = "105--109",

journal = "Journal of Crohn's and Colitis",

issn = "1873-9946",